Document is current
Any future updates will be listed below
-
Authors
Dunlop, Boadie W. https://orcid.org/0000-0002-4653-0483
Cha, Jungho https://orcid.org/0000-0003-1189-2051
Choi, Ki Sueng
Nemeroff, Charles B. https://orcid.org/0000-0001-7867-1160
Craighead, W. Edward https://orcid.org/0000-0001-9957-0027
Mayberg, Helen S. https://orcid.org/0000-0002-1672-2716
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (K23 MH086690, R01 MH080880, P50 MH077083)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
- License Information
-
More Information
Article History
Received: 3 April 2023
Revised: 9 June 2023
Accepted: 26 June 2023
First Online: 25 July 2023
Competing interests
: Dr. Dunlop has received research support from Boehringer Ingelheim, Compass Pathways, NIMH, Otsuka, Sage, Usona Institute, and Takeda and has served as a consultant for Biohaven, Cerebral Therapeutics, Greenwich Biosciences, Myriad Neuroscience, NRx Pharmaceuticals, Otsuka, Sage, and Sophren Therapeutics. Dr. Cha reports no financial relationships with commercial interests. Dr. Choi has served as a consultant for Abbott Laboratories. Dr. Nemeroff has served as a consultant for AbbVie, ANeuroTech (division of Anima BV), Signant Health, Magstim, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Sage, Silo Pharma, Engrail Therapeutics, Pasithea Therapeutic Corp., GoodCap Pharmaceuticals, Inc., Senseye, Clexio, Ninnion Therapeutics, EmbarkNeuro, SynapseBio, BioXcel Therapeutics, and Relmada Therapeutics; he has served on scientific advisory boards ANeuroTech (division of Anima BV), Brain and Behavior Research Foundation (BBRF), Anxiety and Depression Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Heading Health, Pasithea Therapeutic Corp., and Sage; he holds stock in Seattle Genetics, Antares, Inc., Corcept Therapeutics Pharmaceuticals Company, EMA Wellness, Naki Health, Relmada Therapeutics; he serves on the Board of Directors for Gratitude America, ADAA, and Lucy Scientific Discovery, Inc.; and he is named on U.S. patents 6,375,990B1 and 7,148,027B2. Dr. Craighead serves on the National Advisory Board for the George West Mental Health Foundation, as a board member of Hugarheill ehf (an Icelandic company dedicated to the prevention of depression), and as a scientific advisory board member for AIM for Mental Health and the Anxiety and Depression Association of America; he is supported by the Mary and John Brock Foundation, the Pitts Foundation, and the Fuqua family foundations; and he receives book royalties from John Wiley. Dr. Mayberg has received consulting and intellectual property licensing fees from Abbott Neuromodulation.
